首頁 > 市場調查報告書 > 醫療設備

體外診斷液體活檢

市場調查報告書

商品編碼

2131473

癌症液態切片：全球市場

Liquid Biopsy with Emphasis on Cancer: Global Markets

出版日期: 2026年09月04日 | 出版商:

BCC Research | 英文 128 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球腫瘤液態切片市場預計將從 2026 年的 41 億美元成長到 2031 年底的 80 億美元，在 2026 年至 2031 年的預測期內，複合年成長率將達到 14.1%。

調查範圍

本報告概述了全球癌症液態切片市場，並分析了市場趨勢。報告包括以2025年為基準年的全球銷售額（百萬美元）、2026年的估計數據以及2026年至2031年的預測數據。

本報告按適應症、技術、生物標記類型和應用對市場進行細分。依適應症分類，市場涵蓋肺癌、乳癌、大腸癌、攝護腺癌和其他癌症。按技術分類，市場細分為次世代定序(NGS)、聚合酵素鏈鎖反應(PCR) 和其他技術。依生物標記類型分類，本報告涵蓋循環核酸、循環性腫瘤細胞(CTC)、外泌體和循環蛋白。按應用分類，包括治療指南、治療監測、早期癌症篩檢和復發監測。本研究涵蓋的地區包括北美（美國、加拿大、墨西哥）、歐洲（德國、英國、義大利、法國、西班牙和其他歐洲國家）、亞太地區（中國、日本、印度、韓國、澳洲和其他亞太國家）、中東和非洲 (MEA) 以及南美洲，並專注於這些地區的主要國家。

本報告重點在於影響市場和供應商格局的關鍵促進因素和挑戰，並對與市場相關的新興技術進行分析和探討。

本報告最後分析了競爭格局，重點介紹了全球領先的液態切片公司，特別關注腫瘤領域。報告還包含一個專門的公司概況章節，涵蓋公司概要、關鍵財務指標、產品系列和最新發展動態。

報告內容

數據表 64 及補充表 58
全球液態切片技術市場最新綜述與分析。
全球趨勢分析（包括 2023-2025 年的銷售數據、2026 年的估計值以及到 2031 年的複合年成長率預測）
對液態切片技術的整體市場規模進行評估和預測，並按適應症、技術、生物標記類型、臨床應用和地區進行市場佔有率分析。
基於波特五力模型，考慮市場中存在的微觀和宏觀環境因素，進行市場機會分析和產業供應鏈分析。
影響全球市場的市場促進因素、市場限制及其他因素的說明。
本報告涵蓋了不斷發展的技術、當前和未來的市場潛力、研發活動、成長策略、法律規範和保險報銷方案以及市場 ESG 趨勢。
透過專有技術、併購、合資企業和其他策略聯盟，找到最適合滿足此需求的公司。
詳細介紹全球領先公司，包括 Guardant Health、Natera Inc.、Exact Sciences Corp.、Illumina Inc. 和 F. Hoffmann-La Roche Ltd.。

市場動態
市場促進因素
癌症發生率上升
人們越來越重視癌症早期檢測
液態切片相對於傳統組織切片檢查的優勢
市場限制因素
某些液態切片方法的敏感性較低
市場機遇
精準醫療的重要性日益凸顯。
新興市場對癌症診斷的需求不斷成長

第4章監管情勢

美國
歐洲
其他地區

第5章：新興科技與趨勢

新興技術
基於微流體技術的裝置
奈米科技
人工智慧
臨床試驗分析
臨床試驗分析：依研究類型
臨床試驗分析：按狀態
臨床試驗分析：按階段
專利分析
按年份統計的專利數量
由主申請人
由主要所有者
按管轄權

第6章市場區隔分析

細分市場
市場分析：依適應症分類
肺癌
乳癌
結腸癌
攝護腺癌
其他癌症
市場分析：按技術分類
次世代定序（NGS）
聚合酵素鏈鎖反應（PCR）
其他技術
市場分析：依生物標記類型
循環核酸
循環性腫瘤細胞（CTCs）
外泌體
循環蛋白
市場分析：按應用領域
治療監測
復發監測
早期癌症篩檢
治療指導
按地區分類
市場分析：按地區分類
北美洲
歐洲
亞太地區
南美洲
中東和非洲（MEA）

第7章競爭情勢

競爭格局
液態切片市場的領導企業，專注於癌症治療。
Guardant Health
Natera
Exact Science Corp.
主要發展和策略

第8章附錄

調查方法
資訊來源
簡稱
公司簡介
BIO-RAD LABORATORIES INC.
BIO-TECHNE
DXCOVER LTD
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE LTD.
FREEENOME HOLDINGS INC.
GUARDANT HEALTH INC.
ILLUMINA INC.
MYRIAD GENETICS INC.
NATERA INC.
NEOGENOMICS LABORATORIES
NOVIGENIX AI
PERSONALIS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
新興創業公司/市場顛覆者名單

簡介目錄圖表

Product Code: HLC238B

The global market for liquid biopsy with emphasis on cancer is expected to grow from $4.1 billion in 2026 and is projected to reach $8 billion by the end of 2031, at a compound annual growth rate (CAGR) of 14.1% during the forecast period of 2026 to 2031.

Report Scope

The report provides an overview of the global liquid biopsy with an emphasis on cancer market and analyzes market trends. It includes global revenue ($ million), using 2025 as the base year, estimated data for 2026, and projected data from 2026 through 2031.

The report segments the market by indication, technology, biomarker type, and application. By indication, the study includes lung cancer, breast cancer, colorectal cancer, prostate cancer, and other cancers. By technology, the market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies. Based on biomarker type, the report covers circulating nucleic acids, circulating tumor cells (CTCs), exosomes, and circulating proteins. For application, the report includes therapy guidance, therapy monitoring, early cancer screening, and recurrence monitoring. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, with a focus on key countries in these regions.

The report focuses on the key driving trends and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and highlighting the leading global liquid biopsy with an emphasis on cancer companies. It also includes a dedicated section on company profiles that covers overviews, key financials, product portfolios, and recent developments for major companies.

Report Includes

64 data tables and 58 additional tables
An up-to-date review and analysis of the global market for liquid biopsy technologies
Analyses of the global market trends, with sales data for 2023-2025, estimates for 2026, and projections of compound annual growth rates (CAGRs) through 2031
Evaluation and forecast the overall market size for liquid biopsy technologies and their corresponding market share analysis by indication, technology, biomarker type, clinical application, and region
Analysis of market opportunities with a review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro environmental factors prevailing in the market
Explanation of market drivers, restraints and other forces impacting the global market
Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends of the market
Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
Descriptive profiles of the leading global companies, including Guardant Health, Natera Inc., Exact Sciences Corp., Illumina Inc., and F. Hoffmann-La Roche Ltd.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Regional Analysis
Technological Advances
Conclusion

Chapter 2 Market Overview

Overview
Liquid Biopsy Versus Traditional Biopsy
Porter's Five Forces Analysis in the Liquid Biopsy with Emphasis on the Cancer Market
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate)
Threat of Substitutes (Moderate to High)
Competition in the Industry (High)
Macroeconomic Factor Analysis
Cancer Funding
Reimbursement Policy
The U.S. Tariff Scenario

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Rising Incidence of Cancer
Growing Awareness of Early Cancer Detection
Advantages of Liquid Biopsy Over Conventional Tissue Biopsy
Market Restraints
Lower Sensitivity of Certain Liquid Biopsy Procedures
Market Opportunities
Rising Significance of Precision Medicine
Growing Oncology Diagnostics Demand in Emerging Markets

Chapter 4 Regulatory Landscape

U.S.
Europe
Other Regions

Chapter 5 Emerging Technologies and Developments

Emerging Technologies
Microfluidics-Based Devices
Nanotechnology
Artificial Intelligence
Clinical Trials Analysis
Key Takeaways
Clinical Trials Analysis, by Type of Study
Clinical Trials Analysis, by Status
Clinical Trials Analysis, by Phase
Patent Analysis
Key Takeaways
Patents, by Year
By Top Applicant
By Top Owner
By Jurisdiction

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis by Indication
Key Takeaways
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other Cancers
Market Analysis by Technology
Key Takeaways
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Other Technologies
Market Analysis by Biomarker Type
Key Takeaways
Circulating Nucleic Acids
Circulating Tumor Cells (CTCs)
Exosomes
Circulating Protein
Market Analysis by Application
Key Takeaways
Therapy Monitoring
Recurrence Monitoring
Early Cancer Screening
Therapy Guidance
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

Key Takeaways
Competitive Landscape
Leading Companies in the Liquid Biopsy with Emphasis on Cancer Market
Guardant Health
Natera
Exact Science Corp.
Key Developments and Strategies

Chapter 8 Appendix

Methodology
Sources
Abbreviations
Company Profiles
BIO-RAD LABORATORIES INC.
BIO-TECHNE
DXCOVER LTD
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE LTD.
FREEENOME HOLDINGS INC.
GUARDANT HEALTH INC.
ILLUMINA INC.
MYRIAD GENETICS INC.
NATERA INC.
NEOGENOMICS LABORATORIES
NOVIGENIX AI
PERSONALIS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
List of a Few Emerging Start-ups/ Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for Liquid Biopsy with Emphasis on Cancer, by Region,Through 2031
Table 1 : Key Liquid Biopsy Modalities
Table 2 : Liquid Biopsy: Major Biomarker
Table 3 : Liquid Biopsy Versus Traditional Biopsy
Table 4 : Porter's Five Forces Analysis: Overview
Table 5 : Estimated Cancer Incidence, by Region, 2025-2045
Table 6 : Advantages of Liquid Biopsy Over Traditional Tissue Biopsy
Table 7 : Liquid Biopsy Sensitivity, by Cancer, 2025
Table 8 : Other Regions: Liquid Biopsy Regulatory Body
Table 9 : Key Microfluidic Devices for Liquid Biopsy
Table 10 : Clinical Trials in Liquid Biopsy, by Type of Study, March 2026
Table 11 : Clinical Trials in Liquid Biopsy, by Status, March 2026
Table 12 : Clinical Trials in Liquid Biopsy, by Phase, March 2026
Table 13 : Patents, by Top Applicant, 2023-2025
Table 14 : Patents, by Top Owner, 2023-2025
Table 15 : Patents, by Jurisdiction, 2023-2025
Table 16 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 17 : Global Market for Liquid Biopsy with Emphasis on Cancer for Lung Cancer, by Region, Through 2031
Table 18 : Global Market for Liquid Biopsy with Emphasis on Cancer for Breast Cancer, by Region, Through 2031
Table 19 : Global Market for Liquid Biopsy with Emphasis on Cancer for Colorectal Cancer, by Region, Through 2031
Table 20 : Global Market for Liquid Biopsy with Emphasis on Cancer for Prostate Cancer, by Region, Through 2031
Table 21 : Global Market for Liquid Biopsy with Emphasis on Cancer for Other Cancers, by Region, Through 2031
Table 22 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 23 : Global Market for Liquid Biopsy with Emphasis on Cancer for Next-Generation Sequencing , by Region, Through 2031($ Millions)
Table 24 : Global Market for Liquid Biopsy with Emphasis on Cancer for Polymerase Chain Reaction , by Region, Through 2031($ Millions)
Table 25 : Global Market for Liquid Biopsy with Emphasis on Cancer for Other Technologies,by Region, Through 2031
Table 26 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 27 : Circulating Nucleic Acids in Cancer
Table 28 : ctDNA Detection Techniques
Table 29 : Global Market for Liquid Biopsy with Emphasis on Cancer for Circulating Nucleic Acids, by Region, Through 2031
Table 30 : Global Market for Liquid Biopsy with Emphasis on Cancer for Circulating Tumor Cells , by Region, Through 2031($ Millions)
Table 31 : Global Market for Liquid Biopsy with Emphasis on Cancer for Exosomes, by Region, Through 2031
Table 32 : Global Market for Liquid Biopsy with Emphasis on Cancer for Circulating Protein, by Region, Through 2031
Table 33 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 34 : Global Market for Liquid Biopsy with Emphasis on Cancer for Therapy Monitoring, by Region, Through 2031
Table 35 : Global Market for Liquid Biopsy with Emphasis on Cancer for Recurrence Monitoring, by Region, Through 2031
Table 36 : Global Market for Liquid Biopsy with Emphasis on Cancer for Early Cancer Screening, by Region, Through 2031
Table 37 : Global Market for Liquid Biopsy with Emphasis on Cancer for Therapy Guidance, by Region, Through 2031
Table 38 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Region, Through 2031
Table 39 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Country, Through 2031
Table 40 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 41 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 42 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 43 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 44 : European Market for Liquid Biopsy with Emphasis on Cancer, by Country, Through 2031
Table 45 : European Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 46 : European Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 47 : European Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 48 : European Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 49 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Country, Through 2031
Table 50 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 51 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 52 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 53 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 54 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 55 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 56 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 57 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 58 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 59 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 60 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 61 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 62 : Global Market Ranking for Liquid Biopsy with Emphasis on Cancer, 2025
Table 63 : Liquid Biopsy with Emphasis on Cancer: Recent Strategic Developments, 2025-2026
Table 64 : Report Information Sources
Table 65 : Abbreviations Used in the Liquid Biopsy with Emphasis on Cancer Market Report
Table 66 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 67 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2024 and 2025
Table 68 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 69 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024-2025
Table 70 : Bio-Techne: Company Snapshot
Table 71 : Bio-Techne: Financial Performance, FY 2024 and 2025
Table 72 : Bio-Techne: Product Portfolio
Table 73 : Bio-Techne: News/Key Developments, 2024-2025
Table 74 : Dxcover Ltd.: Company Snapshot
Table 75 : Dxcover Ltd.: Product Portfolio
Table 76 : Dxcover Ltd.: News/Key Developments, 2025-2026
Table 77 : Exact Sciences Corp.: Company Snapshot
Table 78 : Exact Sciences Corp.: Product Portfolio
Table 79 : Exact Sciences Corp.: News/Key Developments, 2025
Table 80 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 81 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2024 and 2025
Table 82 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 83 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
Table 84 : Freenome Holdings Inc.: Company Snapshot
Table 85 : Freenome Holdings Inc.: Product Portfolio
Table 86 : Freenome Holdings Inc.: News/Key Developments, 2024-2025
Table 87 : Guardant Health Inc.: Company Snapshot
Table 88 : Guardant Health Inc.: Financial Performance, FY 2024 and 2025
Table 89 : Guardant Health Inc.: Product Portfolio
Table 90 : Guardant Health Inc.: News/Key Developments, 2024-2026
Table 91 : Illumina Inc.: Company Snapshot
Table 92 : Illumina Inc.: Financial Performance, FY 2024 and 2025
Table 93 : Illumina Inc.: Product Portfolio
Table 94 : Illumina Inc.: News/Key Developments, 2024-2025
Table 95 : Myriad Genetics Inc.: Company Snapshot
Table 96 : Myriad Genetics Inc.: Financial Performance, FY 2024 and 2025
Table 97 : Myriad Genetics Inc.: Product Portfolio
Table 98 : Myriad Genetics Inc.: News/Key Developments, 2024-2026
Table 99 : Natera Inc.: Company Snapshot
Table 100 : Natera Inc.: Financial Performance, FY 2024 and 2025
Table 101 : Natera Inc: Product Portfolio
Table 102 : Natera Inc: News/Key Developments, 2025
Table 103 : NeoGenomics Laboratories: Company Snapshot
Table 104 : NeoGenomics Laboratories: Financial Performance, FY 2024 and 2025
Table 105 : NeoGenomics Laboratories: Product Portfolio
Table 106 : NeoGenomics Laboratories: News/Key Developments, 2025-2026
Table 107 : Novigenix AI: Company Snapshot
Table 108 : Novigenix AI: Product Portfolio
Table 109 : Novigenix AI: News/Key Developments, 2024-2026
Table 110 : Personalis Inc.: Company Snapshot
Table 111 : Personalis Inc.: Financial Performance, FY 2024 and 2025
Table 112 : Personalis Inc: Product Portfolio
Table 113 : Personalis Inc.: News/Key Developments, 2024
Table 114 : QIAGEN: Company Snapshot
Table 115 : QIAGEN: Financial Performance, FY 2024 and 2025
Table 116 : QIAGEN: Product Portfolio
Table 117 : QIAGEN: News/Key Developments, 2024-2025
Table 118 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 119 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2024 and 2025
Table 120 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 121 : List of a Few Emerging Start-ups/ Market Disruptors

List of Figures

Summary Figure : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Region, 2025
Figure 1 : Liquid Biopsy: Strengths and Limitations
Figure 2 : Porter's Five Forces Analysis of the Liquid Biopsy with Emphasis on Cancer Market
Figure 3 : Liquid Biopsy with Emphasis on Cancer: Market Dynamics
Figure 4 : CANCER: Estimated Incidence, 2022-2050
Figure 5 : Emerging Trends/Technologies in the Liquid Biopsy with Emphasis on Cancer Market
Figure 6 : Patents Granted, by Year, 2023-2025
Figure 7 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Indication, 2025
Figure 8 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Technology, 2025
Figure 9 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, 2025
Figure 10 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Application, 2025
Figure 11 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Region, 2025
Figure 12 : North American Market Shares of Liquid Biopsy with Emphasis on Cancer, by Country, 2025
Figure 13 : European Market Shares of Liquid Biopsy with Emphasis on Cancer, by Country, 2025
Figure 14 : Asia-Pacific Market Shares of Liquid Biopsy with Emphasis on Cancer, by Country, 2025
Figure 15 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 16 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 17 : Bio-Techne: Revenue Shares, by Business Unit, FY 2025
Figure 18 : Bio-Techne: Revenue Shares, by Country/Region, FY 2025
Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2025
Figure 20 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2025
Figure 21 : Guardant Health Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 22 : Guardant Health Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 23 : Illumina Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 24 : Myriad Genetics Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 25 : Myriad Genetics Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 26 : Natera Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 27 : Personalis Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 28 : QIAGEN: Revenue Shares, by Country/Region, FY 2025
Figure 29 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 30 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2025